

**14 September 2022**

**Statement from Pharmaxis Chair Malcolm McComas and CEO Gary Phillips**

On behalf of everyone at Pharmaxis, we extend deepest sympathies to the family of Pharmaxis' recently retired Director Mr Will Delaat AM, who has passed away in Sydney.

Will made a highly significant contribution to the medicines and biopharma sectors over his long and distinguished 40-year career. His deep knowledge and thoughtful leadership encouraged innovation and medicine access and his work has undoubtedly contributed to the better health of countless patients both here and overseas.

Pharmaxis was fortunate to benefit from Will's experience as a global pharmaceutical industry executive. He served for 14 years on the Pharmaxis Board, fulfilling a key role in the company's evolution including assisting with the international approval and marketing of two innovative respiratory products discovered in Australia, and helping to steer the company's drug discovery and clinical work in fibrosis and inflammation.

Will was a fine example of an executive who treated others with respect. In turn he was held in high regard and affection. He will have a lasting legacy and will be sadly missed.

